Boston Scientific Corporation $BSX Stock Acquired by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 8.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 467,972 shares of the medical equipment provider’s stock after buying an additional 34,959 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Boston Scientific were worth $20,427,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp increased its holdings in shares of Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after acquiring an additional 920,495 shares during the period. BlackRock Inc. purchased a new position in Boston Scientific during the 2nd quarter worth $5,534,781,000. Primecap Management Co. CA purchased a new position in Boston Scientific during the 2nd quarter worth $2,156,233,000. Janus Henderson Group PLC increased its stake in Boston Scientific by 5.2% in the fourth quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider’s stock valued at $1,200,404,000 after purchasing an additional 617,515 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Boston Scientific by 31.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock valued at $1,052,247,000 after purchasing an additional 2,668,230 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward Ludwig bought 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Habiger bought 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 1.0%

Shares of NYSE:BSX opened at $41.98 on Friday. The company has a market cap of $60.83 billion, a price-to-earnings ratio of 16.99, a PEG ratio of 1.00 and a beta of 0.58. The firm’s 50-day simple moving average is $46.64 and its 200-day simple moving average is $50.71. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a fifty-two week low of $41.38 and a fifty-two week high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.25 earnings per share for the current year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific appointed longtime cardiovascular executive Joseph M. Fitzgerald as executive vice president and chief operating officer. Management said the new structure, which organizes operations into three segments, is intended to improve efficiency and support continued growth. Investors may view the move as a potential catalyst for better execution. Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
• Neutral Sentiment: The restructuring is receiving additional coverage because Fitzgerald will oversee the three-segment operating model, including changes affecting the cardiovascular business. The strategy could create longer-term benefits, but investors will need evidence that it improves growth and margins. Why Is Boston Scientific Reorganizing Into Three Segments Under A New COO?
• Neutral Sentiment: Barclays initiated coverage with an “equal weight” rating and later described the shares as “hold.” The rating signals limited near-term conviction rather than a clear bullish or bearish stance. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: BSX reached a new 52-week low during trading, highlighting continued selling pressure and investor concerns despite the announced leadership changes. The stock remains well below its 52-week high, increasing the importance of upcoming execution and earnings results. Boston Scientific Reaches New 1-Year Low
• Negative Sentiment: Citigroup issued a pessimistic forecast for Boston Scientific, adding to the cautious analyst tone around the shares. This offsets some of the potential optimism from the new operating structure. Citigroup Issues Pessimistic Forecast for Boston Scientific

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. UBS Group decreased their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Canaccord Genuity Group dropped their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Needham & Company LLC reduced their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. Evercore set a $65.00 price objective on Boston Scientific in a research report on Monday, July 6th. Finally, Jefferies Financial Group lowered their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Twenty-two research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $66.31.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.